Whole-genome sequencing accurately identifies resistance to extended-spectrum β-lactams for major gram-negative bacterial pathogens

Clinical Infectious Diseases

Volumn 65, Issue 5, 2017, Pages 738-745

  Shelburne, Samuel A ^a,b   Kim, Jiwoong ^c,d   Munita, Jose M ^b,e   Sahasrabhojane, Pranoti ^a   Shields, Ryan K ^f   Press, Ellen G ^f   Li, Xiqi ^a   Arias, Cesar A ^b,g   Cantarel, Brandi ^c   Jiang, Ying ^a   Kim, Min S ^c,d   Aitken, Samuel L ^a,b   Greenberg, David E ^b,d,h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Department of Bioinformatics ^*  (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSIDAD DEL DESARROLLO   (Chile)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNIVERSIDAD EL BOSQUE   (Colombia)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antimicrobial resistance; Bacteremia; Gram negative bacteria; Neutropenic fever; Whole genome sequencing

Indexed keywords

CEFEPIME; CEFTAZIDIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; BACTERIAL DNA;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BLOODSTREAM INFECTION; BROTH DILUTION; COMPARATIVE STUDY; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; GENE MUTATION; GOLD STANDARD; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SENSITIVITY AND SPECIFICITY; WHOLE GENOME SEQUENCING; BACTERIAL GENOME; BETA-LACTAM RESISTANCE; DNA SEQUENCE; DRUG EFFECT; GENETICS; GRAM NEGATIVE INFECTION; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR TYPING; PROCEDURES;

BETA-LACTAM RESISTANCE; DNA, BACTERIAL; GENOME, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 85032194607     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix417     Document Type: Article

References (40)

1. Evans SR, Hujer AM, Jiang H, et al; Antibacterial Resistance Leadership Group. Rapid molecular diagnostics, antibiotic treatment decisions, and developing approaches to inform empiric therapy: PRIMERS I and II. Clin Infect Dis 2016; 62:181-9.
2. Ward C, Stocker K, Begum J, Wade P, Ebrahimsa U, Goldenberg SD. Performance evaluation of the Verigene (Nanosphere) and FilmArray (BioFire) molecular assays for identification of causative organisms in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis 2015; 34:487-96.
3. Walker T, Dumadag S, Lee CJ, et al. Clinical impact of laboratory implementation of verigene BC-GN microarray-based assay for detection of gram-negative bacteria in positive blood cultures. J Clin Microbiol 2016; 54:1789-96.
4. Goodman KE, Lessler J, Cosgrove SE, et al; Antibacterial Resistance Leadership Group. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum β-lactamase-producing organism. Clin Infect Dis 2016; 63:896-903.
5. Caliendo AM, Gilbert DN, Ginocchio CC, et al; Infectious Diseases Society of America (IDSA). Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis 2013; 57(suppl 3):S139-70.
6. Evans SR, Hujer AM, Jiang H, et al. Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics (RMDs) to identify susceptibility and resistance to carbapenems against Acinetobacter spp. PRIMERS III. J Clin Microbiol 2016; 55:134-44.
7. Tuite N, Reddington K, Barry T, Zumla A, Enne V. Rapid nucleic acid diagnostics for the detection of antimicrobial resistance in gram-negative bacteria: is it time for a paradigm shift? J Antimicrob Chemother 2014; 69:1729-33.
8. Kos VN, Deraspe M, McLaughlin RE, et al. The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrob Agents Chemother 2015; 59:427-36.
9. Kos VN, McLaughlin RE, Gardner HA. Elucidation of mechanisms of ceftazidime resistance among clinical isolates of Pseudomonas aeruginosa by using genomic data. Antimicrob Agents Chemother 2016; 60:3856-61.
10. Stoesser N, Batty EM, Eyre DW, et al. Predicting antimicrobial susceptibilities for Escherichia coli and Klebsiella pneumoniae isolates using whole genomic sequence data. J Antimicrob Chemother 2013; 68:2234-44.
11. Pesesky MW, Hussain T, Wallace M, et al. Evaluation of machine learning and rulesbased approaches for predicting antimicrobial resistance profiles in gram-negative bacilli from whole genome sequence data. Front Microbiol 2016; 7:1887.
12. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56-93.
13. Blennow O, Ljungman P. The challenge of antibiotic resistance in haematology patients. Br J Haematol 2016; 172:497-511.
14. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011; 2:65.
15. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22:582-610.
16. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA 2015; 314:1479-87.
17. Jia B, Raphenya AR, Alcock B, et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res 2017; 45:D566-73.
18. Liu B, Pop M. ARDB-antibiotic resistance genes database. Nucleic Acids Res 2009; 37:D443-7.
19. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010; 54:969-76.
20. Guerin F, Isnard C, Cattoir V, Giard JC. Complex regulation pathways of AmpCmediated β-lactam resistance in Enterobacter cloacae complex. Antimicrob Agents Chemother 2015; 59:7753-61.
21. Babouee Flury B, Ellington MJ, Hopkins KL, et al. Association of novel nonsynonymous single nucleotide polymorphisms in ampD with cephalosporin resistance and phylogenetic variations in ampC, ampR, ompF, and ompC in Enterobacter cloacae isolates that are highly resistant to carbapenems. Antimicrob Agents Chemother 2016; 60:2383-90.
22. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009; 22:161-82.
23. Bradford PA, Urban C, Jaiswal A, et al. SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother 1995; 39:899-905.
24. Naas T, Poirel L, Nordmann P. Minor extended-spectrum beta-lactamases. Clin Microbiol Infect 2008; 14(suppl 1):42-52.
25. Zhang Y, Jiang X, Wang Y, et al. Contribution of β-lactamases and porin proteins OmpK35 and OmpK36 to carbapenem resistance in clinical isolates of KPC-2-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2014; 58:1214-7.
26. Goessens WH, van der Bij AK, van Boxtel R, et al. Antibiotic trapping by plasmid-encoded CMY-2 β-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli. Antimicrob Agents Chemother 2013; 57:3941-9.
27. Hentschke M, Kotsakis SD, Wolters M, Heisig P, Miriagou V, Aepfelbacher M. CMY-42, a novel plasmid-mediated CMY-2 variant AmpC beta-lactamase. Microb Drug Resist 2011; 17:165-9.
28. Queenan AM, Shang W, Bush K, Flamm RK. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole. Antimicrob Agents Chemother 2010; 54:4092-7.
29. Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics 2000; 56:345-51.
30. Mathers AJ, Peirano G, Pitout JD. Escherichia coli ST131: the quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol 2015; 90:109-54.
31. Bauer KA, Perez KK, Forrest GN, Goff DA. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clin Infect Dis 2014; 59(suppl 3):S134-45.
32. Fournier PE, Drancourt M, Colson P, Rolain JM, La Scola B, Raoult D. Modern clinical microbiology: new challenges and solutions. Nat Rev Microbiol 2013; 11:574-85.
33. Rhodes NJ, Richardson CL, Heraty R, et al. Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2014; 58:3757-61.
34. Salimnia H, Fairfax MR, Lephart PR, et al. Evaluation of the FilmArray blood culture identification panel: results of a multicenter controlled trial. J Clin Microbiol 2016; 54:687-98.
35. Dunne WM Jr, Westblade LF, Ford B. Next-generation and whole-genome sequencing in the diagnostic clinical microbiology laboratory. Eur J Clin Microbiol Infect Dis 2012; 31:1719-26.
36. McDermott PF, Tyson GH, Kabera C, et al. Whole-genome sequencing for detecting antimicrobial resistance in nontyphoidal Salmonella. Antimicrob Agents Chemother 2016; 60:5515-20.
37. Zhao S, Tyson GH, Chen Y, et al. Whole-genome sequencing analysis accurately predicts antimicrobial resistance phenotypes in Campylobacter spp. Appl Environ Microbiol 2015; 82:459-66.
38. Gordon NC, Price JR, Cole K, et al. Prediction of Staphylococcus aureus antimicrobial resistance by whole-genome sequencing. J Clin Microbiol 2014; 52:1182-91.
39. Thomson KS, Cornish NE, Hong SG, Hemrick K, Herdt C, Moland ES. Comparison of Phoenix and VITEK 2 extended-spectrum-beta-lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized beta-lactamases. J Clin Microbiol 2007; 45:2380-4.
40. Howard C, van Daal A, Kelly G, Schooneveldt J, Nimmo G, Giffard PM. Identification and minisequencing-based discrimination of SHV beta-lactamases in nosocomial infection-associated Klebsiella pneumoniae in Brisbane, Australia. Antimicrob Agents Chemother 2002; 46:659-64.